Athyrium Opportunities Fund IV (AOF IV)

Athyrium Opportunities Fund IV1

Company Description Initial Investment Date
Aris Global HCIT July 2021
Puma Biotechnology, Inc. Biopharma / Nerlynx® July 2021
Aqua Dermatology Dermatology Provider Group October 2021
RVL Pharmaceuticals plc Biopharma / Upneeq® October 2021
Complete Health Partners, Inc. Primary Care Staffing October 2021
TeamHealth Physician Staffing Group October 2021
Team Services Group Home Healthcare Services October 2021
Summit Behavioral Health Behavioral Health November 2021
Oui Therapeutics, Inc. Digital Therapeutics / Suicide Prevention December 2021
Vita Health Digital Therapeutics / Suicide Prevention December 2021
BridgeBio Pharma Inc. Biopharma / Nuliby® and Truseltiq® December 2021
Omeros Corporation Small-Molecule and Protein Therapeutics January 2022
Revance Therapeutics, Inc. Biopharma / Aesthetics March 2022
uMotif eClinical Platform Provider May 2022
Paratek Pharmaceuticals Biopharma / Nuzyra® May 2022
Heartland Veterinary Partners Veterinary July 2022
Kindred Hospice Home Hospice Care August 2022
Basilea Biopharma / Anti-Infectives and Oncology September 2022
Unlock Health Healthcare Digital Marketing February 2023
Calliditas Therapeutics Biopharma / Tarpeyo® December 2023

1. This table lists selected investments made by the Athyrium Opportunities Fund IV.